Anlon HealthcareNSE:AHCL 17 Current Ratio is 2.87 as of Mar. 2026, which is 43% above its 10-year median of 2.01. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, Anlon Healthcare ranks better than 65.9% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Anlon Healthcare's current ratio for the quarter that ended in Mar. 2026 was 2.87.
Anlon Healthcare has a current ratio of 2.87. It generally indicates good short-term financial strength.
The historical rank and industry rank for Anlon Healthcare's Current Ratio or its related term are showing as below:
NSE:AHCL'
s Current Ratio Range Over the Past 10 Years
Min: 1.97 Med: 2.01 Max: 2.87
Current: 2.87
During the past 5 years, Anlon Healthcare's highest Current Ratio was 2.87. The lowest was 1.97. And the median was 2.01.
NSE:AHCL's Current Ratio is ranked better than 65.9% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:AHCL: 2.87
Anlon Healthcare (NSE:AHCL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Anlon Healthcare Current Ratio Related Terms
Anlon Healthcare Current Ratio Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Current Ratio distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anlon Healthcare (NSE:AHCL) has a Current Ratio of 2.87 as of Mar. 2026. This is 43% above median its historical median of 2.01. Over the past decade, Anlon Healthcare's Current Ratio has ranged from 1.97 to 2.87. According to the industry distribution chart, Anlon Healthcare ranks #340 out of 997 companies in the Drug Manufacturers industry, placing it in the top 34.1%.
Is Anlon Healthcare's Current Ratio too high?
Anlon Healthcare's current Current Ratio of 2.87 is 43% above median its 10-year median of 2.01. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 2.87. The Drug Manufacturers industry median Current Ratio is 2.00. Anlon Healthcare's value of 2.87 is 43.5% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #340 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #340 out of 997 companies for Current Ratio. This puts Anlon Healthcare in the upper half of its industry. The industry median Current Ratio is 2.00. Anlon Healthcare's value of 2.87 is 43.5% above this benchmark. Historically, Anlon Healthcare's own Current Ratio has ranged from 1.97 to 2.87 over the past decade. While the company's 10-year median is 2.01 vs. the industry median of 2.00, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current Current Ratio of 2.87 is 43.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current Current Ratio is 2.87, which is 43% above median its own 10-year median of 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Current Ratio of 2.87. The current Current Ratio is 2.87, which is 43% above median its 10-year median of 2.01 and 43.5% above the Drug Manufacturers industry median of 2.00. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Current Ratio is 2.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
